Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer

Exclusion Criteria

• •1. Non-squamous cell carcinoma with EGFR active mutation positive or ALK rearrangement;
• •2. Participants who have received any systemic anti-cancer treatment for thymic epithelial tumor, including surgical treatment, local radiotherapy, cytotoxic drug treatment, targeted drug treatment and experimental treatment;
• •3. Administration of any Chinese medicine against cancer before administration of the drug;
• •4. Participants with other cancer (excluding cervical carcinoma in situ, cured basal cell carcinoma, bladder epithelial tumor \[including TA and tis\]) within five years before the start of this study;
• •5. Participants with any unstable systemic disease (including active infection, uncontrolled hypertension), unstable angina pectoris, angina pectoris starting in the last three months, congestive heart failure (\>= NYHA) Grade II), myocardial infarction (6 months before admission), severe arrhythmia requiring drug treatment, liver, kidney or metabolic diseases;
• •6. With activate or suspectable autoimmune disease, or autoimmune paracancer syndrome requiring systemic treatment;
• •7. Antibiotics were used to treat the infection for 4 weeks prior to the start of the trial;
• •8. Participants who were systemically treated with corticosteroids (prednisone or other corticosteroids \>10 mg/ day) or other immunosuppressive agents within 2 weeks prior to first administration. In the absence of active autoimmune disease, inhaled or topical corticosteroids and adrenal hormone replacement therapy with a dose of less than 10 mg/ day of prednisone are permitted;
• •9. Participants who are allergic to the test drug or any auxiliary materials;
• •10. Participants with active hepatitis B, hepatitis C or HIV;
• •11. The vaccine was administered within 4 weeks of the start of the trial;
• •12. Participants who have undergone major surgery or severe trauma in other systems within 2 months before the start of this trial;
• •13. Pleural effusion, pericardial effusion or ascites that are not clinically controlled and require pleural puncture or abdominal puncture drainage within 2 weeks before inclusion;
• •14. The patients have active pia meningioma, uncontrolled or untreated brain metastases;
• •15. Pregnant or lactating women;
• •16. Participants suffering from nervous system diseases or mental diseases that cannot cooperate;
• •17. Participated in another therapeutic clinical study;
• •18. Other factors that researchers think it is not suitable for enrollment.